Abstract: A peptide that binds to elongation initiation factor 4E (eIF4E) comprising the amino acid sequence CEX1GX2X3X4X5C (SEQ ID NO: 1), where X1 is an amino acid selected from the group consisting of threonine (T), methionine (M) or leucine (L), X2 and X3 is an amino acid selected from the group consisting of phenylalanine (F), modified phenylalanine and tyrosine (Y), X4 and X5 is any amino acid, wherein the two cysteine residues are joined by a disulphide bond. Further, pharmaceutical compositions and uses of the peptide, and pharmaceutical compositions are provided.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1 to R3, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing one or more diseases or disorders associated with integrated stress response.

Abstract: An ophthalmic and associated methods are disclosed. In one example a plurality of ophthalmic tools are located on a single cart for collecting ophthalmic data. Data may be recorded in a standardized format to aid in comparison between records in a database. In one example the standardized format facilitates fast and more accurate diagnoses of ophthalmic conditions.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: The present invention relates to non-membrane disruptive and p53 activating stapled peptides, as well as methods of treatment of cancer involving the use of these peptides. In one embodiment, the peptide comprises or consist of the amino acid sequence of TSFXaa1EY-WXaa3LLXaa2, where Xaa1 is (R)-2-(7?-octenyl)alanine or derivative thereof, or is (R)-2-(4?-pentenyl)alanine or derivative thereof; and Xaa2 and Xaa3 are independently any type of amino acid or modified amino acid. In another embodiment, the peptide comprising or consisting of the amino acid sequence of TSFXaa1EYW Xaa3LLXaa2ENXaa5, wherein Xaa1 and Xaa3 are any type of amino acid or modified amino acid; Xaa2 is S, or P, or (S)-2-(4?-pentenyl)alanine or a derivative of (S)-2-(4?-pentenyl)alanine; and wherein Xaa5 is F or Y.

Abstract: A substance testing method, a substance testing system, and a sensor module for a portable substance testing system is disclosed. The sensor module includes: a light source, configured to illuminate a lateral flow test strip of the portable substance testing system; a filter, comprising a plurality of apertures, configured to filter out light from the lateral flow test strip; and a sensor, for sensing the filtered light, and providing one or more signals indicative of an output of the test strip.

Abstract: An extrusion process for creating a roof ditch molding including forming a main body from a plastic material in a first stage extrusion, conveying the main body through a stacked array of die plates and into a first stage cooling tank, and communicating the main body from an outlet of the first stage cooling tank to a second stage extruder with crosshead die for applying a skim film bonding layer to the main body. Additional steps include applying a decorative layer over the skim bonding layer, communicating the main body to a third stage extruder with cross head die for applying wing portions in partially overlapping fashion along opposite side edges of the decorative layer and drawing the completed ditch molding through a second stage cooling tank prior to conducting one or more finishing operations.

Abstract: A device and method are presented. Largest and smallest successful values of a receive clock delay and a transmit clock delay are determined. A first set of parameters for an SPI coupled to a DDR flash memory are set, including the largest successful values of the transmit clock delay and the receive clock delay, and a first value of a RD cycle. A second set of parameters for the SPI are set, including the smallest successful value of the transmit clock delay and receive clock delay, and a second value of the RD cycle. One of the first and second sets of parameters is selected based on whether the first or second set of parameters results in successfully reading from the DDR flash memory over a larger range of operating temperatures. The SPI is programmed using the selected one of the first and second sets of parameters.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: A network element includes at least two Time Division Multiplexing (TDM) modules each including a TDM client interface, TDM processing circuitry, and circuit emulation circuitry; and a packet switch fabric connected to the at least two TDM modules in a Link Aggregation Group (LAG) for a protected TDM service, and configured to output a packet interface, wherein the protected TDM service is provided as a single packetized TDM stream via the packet interface from the packet switch fabric.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: A network element includes at least two Time Division Multiplexing (TDM) modules each including a TDM client interface, TDM processing circuitry, and circuit emulation circuitry; and a packet switch fabric connected to the at least two TDM modules and configured to output a packet interface, wherein a protected TDM service through the at least two TDM modules is provided as a single packetized TDM stream via the packet interface from the packet switch fabric.

Abstract: Provided herein are certain compounds and imaging agents useful for detecting a condition or disorder associated with protein aggregation, compositions thereof, and methods of their use.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: Systems and methods for generating three-dimensional models with correlated three-dimensional and two dimensional imagery data are provided. In particular, imagery data can be captured in two dimensions and three dimensions. Imagery data can be transformed into models. Two-dimensional data and three-dimensional data can be correlated within models. Two-dimensional data can be selected for display within a three-dimensional model. Modifications can be made to the three-dimensional model and can be displayed within a three-dimensional model or within two-dimensional data. Models can transition between two dimensional imagery data and three dimensional imagery data.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: Systems and methods for generating three-dimensional models with correlated three-dimensional and two dimensional imagery data are provided. In particular, imagery data can be captured in two dimensions and three dimensions. Imagery data can be transformed into models. Two-dimensional data and three-dimensional data can be correlated within models. Two-dimensional data can be selected for display within a three-dimensional model. Modifications can be made to the three-dimensional model and can be displayed within a three-dimensional model or within two-dimensional data. Models can transition between two dimensional imagery data and three dimensional imagery data.